Primary Endpoint Results of the Neuspera Phase II SANS UUI Clinical Study SUFU Presentation

The primary endpoint results of the Neuspera Phase II SANS UUI clinical study will be presented during the annual winter meeting of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), February 26 – March 1, 2025, in Rancho Mirage, California.  These pivotal trial results will support Neuspera’s FDA PMA submission for U.S. regulatory approval and expand the portfolio of clinical evidence Neuspera is building to ensure insurance coding, coverage, and reimbursement.   Our presentation, “Podium #46 – TREATMENT OF OAB SYMPTOMS USING NEUSPERA’S ULTRA-MINIATURIZED SYSTEM: 6-MONTH RESULTS OF THE SANS-UUI PHASE II STUDY” is scheduled for 8:00AM during the OAB/Chemodenervation Podium Session, 7:30-9:00AM on Saturday, March 1^st.  The full SUFU program schedule can be viewed online.